Kornimate/medical-research-clean huggingface dataset:
data collection with the p200te and p200txe

Conditions: Retinal Disease

Summary: the primary objective is to collect oct scans on a modified p200txe and p200te.


Eligibility criteria:
inclusion criteria : * male or female volunteers 22 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed; * volunteers who can follow the instructions by the clinical staff at the clinical site; * volunteers who agree to participate; * volunteers who have been diagnosed with retina pathology with intra-retinal and/or subretinal fluid present in the posterior pole region. exclusion criteria: * volunteers unable to tolerate ophthalmic imaging; * volunteers with ocular media not sufficiently clear to obtain acceptable oct images.
outcomes of pulmonary valve replacement with the inspiris (model 11500a) valve

Conditions: Heart Valve Prosthesis

Summary: the goal of this retrospective chart review is to contribute to the literature on the mid-term durability and hemodynamics of the inspirs resilia bioprosthesis when implanted in children and young adults.

the primary objective of our study is to contribute to the scarce body of literature on the mid-term durability and hemodynamics of the inspiris resilia (model 11500) bioprosthesis when implanted in the pulmonary position in children and young adults. investigators also aim to identify: effect of age on svd, freedom from svd, pathology of svd, valve-related complications, freedom from re-operation, and survival rate.

Eligibility criteria:
inclusion criteria: subjects that have received the inspiris resilia device at participating institutions from 06/2017 through 12/2022. exclusion criteria: subjects that have not received the inspiris resilia device.

Keywords: pulmonary valve replacement pulmonary valve congenital heart disease inspiris resilia
environmental exposures, genetics, and exhaled nitric oxide in pediatric asthma

Conditions: Asthma

Summary: asthma is one of the most common childhood diseases. it is chronic and often severely disabling. the amount of nitric oxide that is exhaled while breathing increases with airway inflammation, a symptom of asthma. this study will examine the results from a previous study, the cincinnati asthma prevention (cap) study, to evaluate the effects of environmental and genetic factors on exhaled nitric oxide (eno) levels and to determine the relationship between eno and asthma severity.

nitric oxide is a naturally occurring gas that plays a role in many body functions. levels of eno increase with airway inflammation, a symptom of asthma. researchers have proposed using eno as a noninvasive measure to guide physicians in the treatment and medical management of asthma in children. however, more information about eno is needed before this can happen. this study will perform a secondary analysis of the results from its parent study, the cap study, which evaluated the effectiveness of preventing asthma in children who had been exposed to environmental tobacco smoke. this study will not enroll any new participants. previously collected data from the cap study will be reevaluated in this study to determine the longitudinal effects of environmental and genetic factors on eno levels. in addition, the data will be evaluated to determine the relationship between eno levels and asthma severity. no new data will be collected in this study.

Eligibility criteria:
inclusion criteria: * participated in the cincinnati asthma prevention study * diagnosis of asthma * lives with someone that smokes at least 5 cigarettes a day exclusion criteria: * no additional neuromuscular or respiratory disorder that may interfere with safe participation in the parent study * does not have electricity * plans to move within 1 year of entry into the parent study

Keywords: exhaled nitric oxide asthma tobacco smoke allergen
assessing gs500 in functional constipation

Conditions: Constipation - Functional

Summary: this study is designed to evaluate the safety, tolerability and efficacy of gs500 as a superabsorbent hydrogel for relief of constipation in subjects with functional constipation.

to evaluate the safety, tolerabilityand efficacy of gs500 as a superabsorbent hydrogel for relief of constipation in subjects with functional constipation.

Eligibility criteria:
inclusion criteria: * age ≥18 and ≤75 years old * bmi ≥18.5 and \<35 kg/m2 * rome iv criteria for fc * compliant with reporting during baseline run-in . * ability to record daily bowel habits, including frequency, stool consistency, straining, completeness of evacuation, and patient reported outcomes * ability to follow verbal and written instructions * consent obtained via signed icf exclusion criteria: * meeting rome iv criteria for ibsat screening * missing \> 2 days of daily bowel habits reporting during either week of the baseline run-in period * patients reporting laxative, enema, and/or suppository usage for \>2 days or any usage of a prohibited medication during the baseline run-in * patients reporting watery stools for any sbm or loose stools for \>1 sbm in the absence of laxatives during baseline run-in * need for routine manual maneuvers in the last 6 months in order to achieve a bm * history of significant gi lumen surgery at any time or other gi or abdominal surgery except cholecystectomy or appendectomy within 2 months prior to screening * documented gi obstruction * history of laxative abuseas judged by investigator team * glycosylated hemoglobin (hba1c) ≥8.5% * known history of crohn's disease or ulcerative colitis * pregnancy in females of childbearing potential or lactation * absence of medically approved contraception in females of childbearing potential * history of allergic reaction to carboxymethylcellulose, citric acid, sodium stearyl fumarate, hpmc, pectin, gelatin, maltotextrin or titanium dioxide * currently enrolled in another investigational device or drug study, or less than 3 months since ending another investigational device or drug study(s), or receiving other investigational treatment(s). * subjects anticipating surgical intervention during the study * angina, coronary bypass, or myocardial infarction within 6 months prior to screening visit * history of swallowing disorders * history of gastroparesis * history of intestinal stricture (e.g., crohn's disease) * history of intestinal obstruction or subjects at high risk of intestinal obstruction including suspected small bowel adhesions * history of maltodextrin intolerance * presence of metastatic cancer or current use of systemic anti-cancer treatments * anticipated requirement for use of prohibited concomitant medications * current use of prescribed or illicit opioids * use of intestinal secretagogues to treat constipation/ibs within 12 months of the screening visit * any other clinically significant disease or biochemical abnormality interfering with the assessments of gs500, according to the investigator
secondary cytoreductive surgery in platinum-resistant recurrent ovarian cancers

Conditions: Ovarian Cancer; Recurrent Ovarian Carcinoma

Summary: this novel study was specifically designed for platinum resistant recurrent ovarian cancers and aimed to compare cases who received secondary cytoreductive surgery for isolated recurrence and chemotherapy versus chemotherapy alone. this comparison will conduct the intraoperative events, postoperative morbidity and mortality, pathological outcomes and long-term oncological outcomes as regarding progression free survival and overall survival rates.

baseline postoperative imaging with the use of abdominopelvic ct or mri was to be completed during a 28-day window in which chemotherapy was initiated. disease is also assessed after cycles 3 and 6 of trial treatment (and after cycle 8, if administered), every 3 months for 2 years, and then every 6 months thereafter. physical examinations will be performed, and serum ca-125 levels measured at the beginning of each cycle of chemotherapy. treatment-free interval (6 to 12 months or \>12 months after the last chemotherapy infusion) will be reported.

Eligibility criteria:
inclusion criteria: * platinum-resistant, recurrent epithelial ovarian cancer * amenable to complete gross resection, isolated recurrence * adequate renal, hepatic, and bone marrow function, * performance-status ecog score of 0 to 2. exclusion criteria: * not medically fit for surgery * diffuse carcinomatosis, ascites, or extra-abdominal disease

Keywords: ovarian cancer platinum resistant cytoreductive surgery recurrent ovarian cancer complete resection
the exploratory study about the effect of using double filtration plasmapheresis (dfpp) removing inflammatory cytokines, lipids and toxic metal ions in peripheral blood in adults

Conditions: Sub-healthy; Hyperlipidemia; Toxic Metal Ions Accumulation

Summary: this study investigates whether using double filtration plasmapheresis (dfpp) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood. it's also postulated that dfpp could boost immune cells through removing certain inflammatory cytokines and blood lipids.

in this study, 3 groups of subjects will be recruited based on the indications of using dfpp. estimated 100 sub-healthy subjects will be enrolled in the group a (inflammatory cytokine group), the inflammatory cytokine panel will be tested at baseline, immediately and 1, 3, 6 months after using dfpp. similarly estimated 100 subjects with elevated blood lipid or cholesterol will be enrolled in group b (lipids group), the lipid panel will be tested at the same timeline as group a. estimated 50 subjects who are likely to have toxic metal ions accumulated (eg. using make-up for long term, working exposure) will be enrolled in group c (toxic metal ions group), the specific metal ions will be tested before and after using dfpp. tests related to immune cells will also be conducted in group a and b at baseline, immediately and 1, 3, 6 months after using dfpp.

Eligibility criteria:
inclusion criteria: * male/females of 18 to 85 years of age. for group b, subjects should have elevated blood lipid or cholesterol, which could be a. hyperlipidemia; b. higher than the normal range but not high enough to be diagnosed as hyperlipidemia. able to provide written informed consent. able to follow verbal and written study directions. exclusion criteria: * have sever liver and kidney dysfunction. have cardiopulmonary insufficiency. have solid or blood tumor. pregnancy or breastfeeding women.

Keywords: dfpp blood purification
the sakakibara health integrative profile of atherosclerotic-carcinogenesis hypothesis (ship-ac)

Conditions: Cancers; Atheroscleroses, Coronary; Atherosclerosis of Artery

Summary: as previously reported (ijc heart \& vasculature 2017; 17: 11.), our epidemiological analysis showing high incidence of cancers in patients with atherosclerotic cardiovascular diseases as compared with those with non-atherosclerotic cardiovascular diseases may imply a clinical possibility of a role of atherosclerosis in cancer developments. in the present study, to address our hypothesis that cancer developments may come with a strength of atherosclerosis, we traced an incidence of cancers in a total of 8,856 patients with coronary artery diseases (cad) for a median follow-up of 1,095 days (interquartile range, 719-1,469 days) using the sakakibara health integrative profile (ship) database.

in accordance with a presence or absence of poly-arterial diseases such as aortic and/or peripheral artery diseases as an indicator of a strength of atherosclerosis, an incidence of cancers and all-cause death in two cohorts of 8,140 patients with cad-only and 716 with cad with poly-arterial diseases were evaluated to track an incidence of cancers and ali-cause mortality during median follou-up periods of 3 to 4 years.

Eligibility criteria:
inclusion criteria: * patients with diagnosed coronary artery diseases without a dignosis of cancers at the entry of ship between january 2009 and july 2014. exclusion criteria: * patients with diagnosed coronary artery diseases who had already been diagnosed with any cancers at the time of enrollment in the ship, and who were not followed-up after the entry of ship.

Keywords: atherosclerosis, cancers
ultra-short anatomic and conventional cementless stems cementless stems in patients younger than fifty-five years old

Conditions: Hip Replacement, Total; Osteonecrosis of Femoral Head; Coxarthrosis

Summary: as clinical and radiographic performance of an ultra-short anatomic cementless stem have been investigated only two randomized controlled studies, well-designed trials should aim for a thorough comparison of the outcomes of ultra-short and conventional cementless stems. the purpose of this study was to compare the outcomes of ultra-short and conventional stems in the same young patients who underwent simultaneous bilateral sequential total hip arthroplasties.

conventional cementless femoral stems are known to provide a high rate of satisfactory clinical outcomes at long-term follow-ups. however, they may have potential clinical consequences related to stress shielding, thigh pain, periprosthetic fractures, proximal/distal dimensional mismatch, an easier access pathway for wear debries and removal during revision. in an effort to reduce the risk of stress shielding, thigh pain, periprosthetic fracture, proximal/distal stem mismatch, and to facilitate removal of well fixed stem, a new ultra-short anatomic metaphyseal-fitting cementless femoral stem was developed. it was designed to provide closely mimicking the original functioning hip. the absence of the diaphyseal anchorage attempt proximal load transfer to reduce stress shielding, thigh pain and proximal distal/mismatch. furthermore, it attempts to preservation of the femoral canal and femoral elasticity and ease of revision. the question thus arises whether it is possible to obtain strong and long-lasting fixation of the femoral component without diaphyseal anchoring. as clinical and radiographic performances of this ultra-short stem have been investigated only in a few studies and at short-term follow-ups, it remains to be elucidated whether an ultra-short stem shows a low incidence of implant loosening, stem misalignment, intraoperative fractures and revision rate. the purpose of this randomized controlled study to compare: (1) the clinical results, including harris hip score, thigh pain, western ontario and mcmaster universities osteoarthritis (womac) index score, and patients' satisfaction; (2) radiographic results, including stress shielding, implant loosening, stem misalignment; and (3) intraoperative fractures and revision rates of cementless total hip arthroplasty using an ultra-short anatomic metaphyseal-fitting cementless femoral stem versus a conventional metaphyseal and diaphyseal fitting anatomi proximal porous-coated cementless stem in the same patients who underwent bilateral simultaneous sequential total hip arthroplasty under one anesthetic.

Eligibility criteria:
inclusion criteria: * end stage hip arthritis exclusion criteria: * age above 50 years old * inflammatory arthritis * coexisting foot or ankle disorder limiting walking
clinical study of magnetic resonance imaging and deep learning of joint synovial disease

Conditions: Synovial Diseases; Pigmented Villonodular Synovitis; Gout; Rheumatoid Arthritis

Summary: through the high-throughput feature extraction of magnetic resonance images, the deep learning prediction model of joint synovial lesions is constructed used for the diagnosis, differential diagnosis and curative effect monitoring of joint synovial lesions.

the study applies magnetic resonance and deep learning (dl) to the diagnosis of joint synovial lesions, aims to have a more comprehensive understanding of the pathophysiology of the occurrence and development of joint synovial lesions. as a non-invasive imaging method to assess the condition of the disease, dl methods excavates the deep features contained in the image, quantifies the joint synovial lesions, and then gives more information to the clinician in the diagnosis and differential diagnosis of the joint synovial lesions, provide important information for the planning of individualized treatment plans for patients with joint synovial diseases.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with joint synovial disease through radiological examination, arthroscopy or pathological biopsy of the joint, or whose clinical manifestations meet the diagnostic criteria of the american college of rheumatology (acr) for joint synovial disease. 2. patients received pre-treatment mr. exclusion criteria: 1. patients who have received surgery, medication or other systemic treatment before standardized mri scan. 2. poor image quality. 3. articular hemorrhage.

Keywords: pigmented villonodular synovitis deep learning knee synovitis mri
prognosis and virulence determination of capsule and endotoxin during klebsiella spp. ventilator-associated pneumonias

Conditions: Ventilator-associated Pneumonia

Summary: ventilator-associated pneumonia is the leading cause of nosocomial infection in the icu. the pathogens responsible are multiple, but enterobacteria constitute a major source of pathogens involved. within this family, klebsiella spp. and escherichia coli are the two most frequent genera, with klebsiella spp. often present in severe forms. the factors associated with the occurrence of ventilator-associated pneumonia and its adverse course depend on host defenses and the virulence of the pathogen. the virulence of klebsiella spp. depends on several structures, notably the presence of a capsule, the particularities of its lipopolysaccharide, its adhesins (type 3 fimbriae), its capacity to capture iron (siderophores). the objective of this work is to evaluate the role of these different virulence mechanisms in the evolution of ventilator-associated pneumonia and the hospital prognosis.


Eligibility criteria:
inclusion criteria: * patient whose age is ≥ 18 years * patient hospitalized in an intensive care unit * patient with ventilator-associated klebsiella spp. pneumonia * french-speaking patient exclusion criteria: * patient with a severe psychiatric disorder * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * patient who objects to the use of his or her data for this research
phase 3 randomized double-blind placebo-controlled study of nrp104 in children aged 6-12 with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this study is designed to assess efficacy and safety of nrp-104 administered as a daily dose of 30mg, 50mg or 70mg compared to placebo in the treatment of children aged 6-12 years with adhd.


Eligibility criteria:
inclusion criteria: * primary diagnosis of adhd combined subtype or the predominantly hyperactive-impulsive subtype based on a psychiatric evaluation that reviews dsm-iv criteria * functioning at age appropriate levels intellectually * blood pressure measurements within the 95th percentile for their gender, height and age * ecg results are within the normal range exclusion criteria: * comorbid psychiatric diagnosis (such as psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, severe depressive or severe anxiety disorder) or other symptomatic manifestations * history of seizures (exclusive of febrile seizure), a tic disorder, or a family history of tourette's disorder * weighs less than 55 lbs (25 kg)or is significantly overweight or obese * clinically significant ecg abnormality * documented allergy or intolerance to amphetamines
studies in porphyria iii: heme and tin mesoporphyrin in acute porphyrias

Conditions: Porphyria

Summary: objectives: i. compare the efficacy of heme arginate, singly or in combination with tin mesoporphyrin, in lowering porphyrin precursors in patients with asymptomatic acute intermittent porphyria. ii. evaluate and compare the safety and tolerability of these treatment regimens in this patient population.

protocol outline: this is an unblinded, dose ranging study. patients receive heme arginate alone or in combination with tin mesoporphyrin. patients receive tin mesoporphyrin iv as a single dose. heme arginate is administered as a single intravenous infusion. patients are entered in cohorts of 4. subsequent cohorts of 4 patients each receive escalating doses of tin mesoporphyrin in combination with 1 of 2 different dosages of heme arginate. subjects must maintain a constant diet. patients experiencing adverse reactions are followed as clinically indicated.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- * documented acute intermittent porphyria in remission for at least 1 month * increased excretion of porphyrin precursors * absence of neurovisceral symptoms due to porphyria for at least 1 month --prior/concurrent therapy-- * at least 1 month since prior heme preparation therapy * concurrent medication for coexisting condition is allowed, as long as dose and pattern of administration is held constant during study --patient characteristics-- * renal: urinary porphobilinogen excretion of at least 20 mg every 24 hours * other: not pregnant fertile female patients must use effective contraception during and at least 6 months before study at least 1 month since any symptoms of disease no concurrent acute hemorrhagic disorder such as: gastrointestinal bleeding intracerebral hemorrhage no known hypersensitivity to heme arginate, tin mesoporphyrin, another heme preparation, or related heme analogue no other condition that may increase risk to patient

Keywords: inborn errors of metabolism porphyria rare disease
questionnaires to identify chinese patients at risk for obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to validate the berlin questionnaire and stop-bang (snore, tired, obstruction, pressure, body mass index (bmi), age, neck, gender) as effective screening tools for chinese subjects who are suspected to have obstructive sleep apnea (osa).

obstructive sleep apnea (osa) is a common sleep related breathing disorder associated with excessive daytime sleepiness and cardiovascular disease. it is prevalent in both western (4-26%) and eastern countries (4-19%). in recent studies, it has been estimated that at least 70-80% of middle aged individuals with sleep apnea are undiagnosed and untreated. the prevalence of undiagnosed osa subjects within the community suggests the need for a greater awareness and a high index of suspicion of this disease entity as well as its associated short- and long-term comorbidities. a reliable and easy-to-use screening questionnaire is required for efficient prediction of osa and treatment arrangement. it would be helpful to prioritize patients who require sleep study according to the probability of suffering from sleep apnea. it reduces the use of sleep study for those with low probability of having osa, but giving treatment to those who are with more severe osa first. meanwhile, it enhances the cost effective management of disease especially with limited resources in our society.

Eligibility criteria:
inclusion criteria: a. no known history of any sleep disorder exclusion criteria: 1. history of heavy alcoholism ( ≥ 3 times / week) 2. underlying pulmonary diseases 3. recent upper respiratory tract infection in the past one week 4. unstable medical conditions 5. pregnancy 6. history of psychiatric illness

Keywords: sleep apnea questionnaire